CRVS

Corvus Pharmaceuticals, Inc.

Price Chart

Latest Quote

$11.91

-0.09 (-0.75%)

Current Price

Previous Close	$12.00
Open	$12.36
Day High	$12.58
Day Low	$11.72
Volume	1,977,181

Fetched: 2026-06-22T08:25:20

Stock Information

Shares Outstanding	84.09M
Total Debt	$834K
Cash Equivalents	$236.71M
Net Income	$-44.17M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$1.00B
EPS (TTM)	$-0.55
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$765.64M
Income	$-44.17M
Book/sh	$2.86
Cash/sh	$2.81
Employees	37

Financial Ratios

Quick Ratio	19.65
Current Ratio	19.81
Debt/Eq	0.35

Returns & Margins

ROA	-19.16%
ROE	-30.46%

Ownership

Insider Ownership	3.51%
Institutional Ownership	85.47%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-12.58
P/B	4.16

Analyst Data

Recommendation	strong_buy
Target Price	$33.33

Technical Indicators

SMA20	$11.96
SMA50	$13.86
SMA200	$11.84
RSI	41.38
ATR	0.6496

Shares Float	72.76M
Short Float	23.42%
Short Ratio	9.62
Volatility	0.84
Rel Volume	1.38

Performance History

Week	+2.67%
Month	+3.57%
Quarter	-15.47%
6 Months	+50.00%
YTD	+62.70%
Year	+202.28%
3 Years	+259.82%
5 Years	+325.36%
10 Years	-7.46%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$11.91	1,977,200
2026-06-17	$12.00	1,171,600
2026-06-16	$11.74	1,181,400
2026-06-15	$11.90	707,800
2026-06-12	$11.93	1,022,200
2026-06-11	$11.60	1,140,000
2026-06-10	$11.16	1,506,800
2026-06-09	$11.17	1,624,200
2026-06-08	$11.15	915,700
2026-06-05	$11.12	1,182,100
2026-06-04	$11.72	807,000
2026-06-03	$11.60	1,602,000
2026-06-02	$11.69	1,912,800
2026-06-01	$12.08	1,580,700
2026-05-29	$12.41	3,398,800
2026-05-28	$12.50	1,675,100
2026-05-27	$12.93	1,244,800
2026-05-26	$12.83	844,100
2026-05-22	$12.61	1,180,600
2026-05-21	$13.08	1,891,900
2026-05-20	$12.19	2,187,500
2026-05-19	$11.50	3,920,700

About Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.

📰 Latest News

Corvus Pharmaceuticals Faces Key Soquelitinib Data And Possible M&A Interest

Simply Wall St. • 2026-06-14T22:09:44Z

Is Corvus Pharmaceuticals, Inc. (CRVS) A Good Stock To Buy Now?

Insider Monkey • 2026-06-13T15:53:35Z

Adams Street Partners Exits Its 223,000-Share Paymentus (PAY) Position for $5.9 Million

Motley Fool • 2026-05-24T13:42:05Z

Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase

Motley Fool • 2026-05-17T20:46:06Z

Return To Losses And New Shelf Offering Might Change The Case For Investing In Corvus Pharmaceuticals (CRVS)

Simply Wall St. • 2026-05-10T09:08:43Z

Assessing Corvus Pharmaceuticals (CRVS) Valuation After Rapid Multi‑Year Share Price Gains

Simply Wall St. • 2026-03-13T20:08:18Z

Corvus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary

Moby • 2026-03-13T12:30:00Z

Corvus (CRVS) Q4 2025 Earnings Call Transcript

Motley Fool • 2026-03-13T03:30:23Z

Corvus Pharmaceuticals Inc (CRVS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com • 2026-03-13T03:07:41Z

Corvus Pharmaceuticals Q4 Earnings Call Highlights

MarketBeat • 2026-03-12T22:46:43Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$42,971,000	$27,548,000	$23,407,000	$32,565,000
Other Income Expense	$25,183,000	$-36,569,000	$-5,206,000	$-9,396,000
Net Non Operating Interest Income Expense	$2,505,000	$1,824,000	$1,584,000	$654,000
Operating Expense	$42,971,000	$27,548,000	$23,407,000	$32,565,000
General And Administrative Expense	$9,252,000	$8,163,000	$6,881,000	$8,097,000
Other Non Operating Income Expenses	-	-	$78,000	$587,000
Total Other Finance Cost	-	-	$-1,584,000	$-654,000
Interest Expense	-	-	-	-
Interest Expense Non Operating	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-15,283,000	$-62,293,000	$-27,029,000	$-41,307,000
Net Interest Income	$2,505,000	$1,824,000	$1,584,000	$654,000
Interest Income	$2,505,000	$1,824,000	$1,584,000	$654,000
Normalized Income	$-42,424,000	$-28,921,000	$-27,029,000	$-41,329,000
Net Income From Continuing And Discontinued Operation	$-15,283,000	$-62,293,000	$-27,029,000	$-41,307,000
Total Operating Income As Reported	$-42,971,000	$-27,548,000	$-23,407,000	$-32,565,000
Net Income Common Stockholders	$-15,283,000	$-62,293,000	$-27,029,000	$-41,307,000
Net Income	$-15,283,000	$-62,293,000	$-27,029,000	$-41,307,000
Net Income Including Noncontrolling Interests	$-15,283,000	$-62,293,000	$-27,029,000	$-41,307,000
Net Income Continuous Operations	$-15,283,000	$-62,293,000	$-27,029,000	$-41,307,000
Pretax Income	$-15,283,000	$-62,293,000	$-27,029,000	$-41,307,000
Special Income Charges	$0	$5,000	$0	$22,000
Earnings From Equity Interest	$-1,958,000	$-3,197,000	$-5,284,000	$-10,005,000
Interest Income Non Operating	$2,505,000	$1,824,000	$1,584,000	$654,000
Operating Income	$-42,971,000	$-27,548,000	$-23,407,000	$-32,565,000
Per Share
Diluted EPS	$-0.53	$-1.02	$-0.56	$-0.89
Basic EPS	$-0.19	$-1.02	$-0.56	$-0.89
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-70,007,000	$5,909,000	$-23,256,000	$-32,220,000
Total Unusual Items	$27,141,000	$-33,372,000	$0	$22,000
Total Unusual Items Excluding Goodwill	$27,141,000	$-33,372,000	$0	$22,000
Reconciled Depreciation	$105,000	$85,000	$151,000	$367,000
EBITDA (Bullshit earnings)	$-42,866,000	$-27,463,000	$-23,256,000	$-32,198,000
EBIT	$-42,971,000	$-27,548,000	$-23,407,000	$-32,565,000
Diluted Average Shares	$79,742,685	$60,985,165	$48,025,274	$46,553,511
Basic Average Shares	$78,964,842	$60,985,165	$48,025,274	$46,553,511
Diluted NI Availto Com Stockholders	$-15,283,000	$-62,293,000	$-27,029,000	$-41,307,000
Gain On Sale Of Ppe	$0	$5,000	$0	$22,000
Gain On Sale Of Security	$27,141,000	$-33,377,000	-	-
Research And Development	$33,719,000	$19,385,000	$16,526,000	$24,468,000
Selling General And Administration	$9,252,000	$8,163,000	$6,881,000	$8,097,000
Other Gand A	$9,252,000	$8,163,000	$6,881,000	$8,097,000

Fetched: 2026-06-20

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$61,205,000	$32,568,000	$38,684,000	$56,115,000
Total Assets	$71,119,000	$68,907,000	$45,553,000	$68,240,000
Total Non Current Assets	$12,905,000	$14,500,000	$17,597,000	$24,576,000
Other Non Current Assets	$855,000	$632,000	$89,000	$129,000
Current Assets	$58,214,000	$54,407,000	$27,956,000	$43,664,000
Other Current Assets	$318,000	$548,000	$220,000	$102,000
Prepaid Assets	$772,000	$1,679,000	$524,000	$626,000
Receivables	$374,000	$216,000	$63,000	$633,000
Accrued Interest Receivable	$337,000	$141,000	$37,000	$45,000
Accounts Receivable	$37,000	$75,000	$26,000	$588,000
Cash Cash Equivalents And Short Term Investments	$56,750,000	$51,964,000	$27,149,000	$42,303,000
Cash And Cash Equivalents	$4,576,000	$8,740,000	$12,620,000	$13,159,000
Debt
Total Debt	$937,000	$1,122,000	$1,374,000	$2,601,000
Long Term Debt And Capital Lease Obligation	$534,000	$937,000	$0	$1,373,000
Current Debt And Capital Lease Obligation	$403,000	$185,000	$1,374,000	$1,228,000
Liabilities
Total Liabilities Net Minority Interest	$9,914,000	$36,339,000	$6,869,000	$12,125,000
Total Non Current Liabilities Net Minority Interest	$534,000	$937,000	$0	$1,373,000
Current Liabilities	$9,380,000	$35,402,000	$6,869,000	$10,752,000
Other Current Liabilities	$238,000	$29,199,000	$245,000	$158,000
Payables And Accrued Expenses	$8,098,000	$5,198,000	$4,566,000	$8,253,000
Payables	$2,491,000	$2,582,000	$1,525,000	$1,976,000
Accounts Payable	$2,491,000	$2,582,000	$1,525,000	$1,976,000
Equity
Common Stock Equity	$61,205,000	$32,568,000	$38,684,000	$56,115,000
Total Equity Gross Minority Interest	$61,205,000	$32,568,000	$38,684,000	$56,115,000
Stockholders Equity	$61,205,000	$32,568,000	$38,684,000	$56,115,000
Gains Losses Not Affecting Retained Earnings	$-896,000	$-1,288,000	$-967,000	$-563,000
Other Equity Adjustments	$-896,000	$-1,288,000	$-967,000	$-563,000
Retained Earnings	$-412,293,000	$-397,010,000	$-334,717,000	$-307,688,000
Long Term Equity Investment	$10,991,000	$12,540,000	$16,123,000	$21,877,000
Other
Ordinary Shares Number	$74,696,629	$67,899,779	$49,038,582	$46,553,511
Share Issued	$74,696,629	$67,899,779	$49,038,582	$46,553,511
Tangible Book Value	$61,205,000	$32,568,000	$38,684,000	$56,115,000
Invested Capital	$61,205,000	$32,568,000	$38,684,000	$56,115,000
Working Capital	$48,834,000	$19,005,000	$21,087,000	$32,912,000
Capital Lease Obligations	$937,000	$1,122,000	$1,374,000	$2,601,000
Total Capitalization	$61,205,000	$32,568,000	$38,684,000	$56,115,000
Additional Paid In Capital	$474,387,000	$430,859,000	$374,363,000	$364,361,000
Capital Stock	$7,000	$7,000	$5,000	$5,000
Common Stock	$7,000	$7,000	$5,000	$5,000
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$534,000	$937,000	$0	$1,373,000
Current Capital Lease Obligation	$403,000	$185,000	$1,374,000	$1,228,000
Pensionand Other Post Retirement Benefit Plans Current	$641,000	$820,000	$684,000	$1,113,000
Current Accrued Expenses	$5,607,000	$2,616,000	$3,041,000	$6,277,000
Investments And Advances	$10,991,000	$12,540,000	$16,123,000	$21,877,000
Investmentsin Associatesat Cost	$10,991,000	$12,540,000	$16,123,000	$21,877,000
Net PPE	$1,059,000	$1,328,000	$1,385,000	$2,570,000
Accumulated Depreciation	$-2,649,000	$-4,626,000	$-4,697,000	$-4,546,000
Gross PPE	$3,708,000	$5,954,000	$6,082,000	$7,116,000
Leases	$33,000	$2,084,000	$2,084,000	$2,084,000
Other Properties	$3,485,000	$3,699,000	$3,827,000	$4,890,000
Machinery Furniture Equipment	$190,000	$171,000	$171,000	$142,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$52,174,000	$43,224,000	$14,529,000	$29,144,000
Duefrom Related Parties Current	-	-	-	$588,000
Buildings And Improvements	-	-	-	-

Fetched: 2026-06-20

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-32,971,000	$-25,424,000	$-23,969,000	$-27,292,000
Operating Activities
Operating Cash Flow	$-32,797,000	$-25,424,000	$-23,935,000	$-27,023,000
Cash Flow From Continuing Operating Activities	$-32,797,000	$-25,424,000	$-23,935,000	$-27,023,000
Operating Gains Losses	$-25,183,000	$36,569,000	$5,284,000	$9,983,000
Investing Activities
Capital Expenditure	$-174,000	-	$-34,000	$-269,000
Investing Cash Flow	$-7,796,000	$-27,484,000	$15,541,000	$-23,276,000
Cash Flow From Continuing Investing Activities	$-7,796,000	$-27,484,000	$15,541,000	$-23,276,000
Financing Activities
Issuance Of Capital Stock	$0	$16,405,000	$7,843,000	$0
Financing Cash Flow	$36,429,000	$49,028,000	$7,855,000	$0
Cash Flow From Continuing Financing Activities	$36,429,000	$49,028,000	$7,855,000	$0
Net Common Stock Issuance	$0	$16,405,000	$7,843,000	$0
Common Stock Issuance	$0	$16,405,000	$7,843,000	$0
Other
End Cash Position	$4,576,000	$8,740,000	$12,620,000	$13,159,000
Beginning Cash Position	$8,740,000	$12,620,000	$13,159,000	$63,458,000
Changes In Cash	$-4,164,000	$-3,880,000	$-539,000	$-50,299,000
Proceeds From Stock Option Exercised	$36,429,000	$32,623,000	$12,000	$0
Net Investment Purchase And Sale	$-7,622,000	$-27,489,000	$15,575,000	$-23,029,000
Sale Of Investment	$84,128,000	$42,630,000	$62,623,000	$43,162,000
Purchase Of Investment	$-91,750,000	$-70,119,000	$-47,048,000	$-66,191,000
Net PPE Purchase And Sale	$-174,000	$5,000	$-34,000	$-247,000
Sale Of PPE	$0	$5,000	$0	$22,000
Purchase Of PPE	$-174,000	$0	$-34,000	$-269,000
Change In Working Capital	$3,579,000	$-1,647,000	$-3,594,000	$1,412,000
Change In Other Current Liabilities	$-185,000	$-252,000	$-1,227,000	$-1,046,000
Change In Other Current Assets	$115,000	$-571,000	$1,108,000	$1,080,000
Change In Payables And Accrued Expense	$2,670,000	$812,000	$-4,029,000	$878,000
Change In Accrued Expense	$2,761,000	$-245,000	$-3,578,000	$467,000
Change In Payable	$-91,000	$1,057,000	$-451,000	$411,000
Change In Account Payable	$-91,000	$1,057,000	$-451,000	$411,000
Change In Prepaid Assets	$941,000	$-1,587,000	$-8,000	$581,000
Change In Receivables	$38,000	$-49,000	$562,000	$-81,000
Changes In Account Receivables	$38,000	$-49,000	$562,000	$-81,000
Stock Based Compensation	$5,330,000	$3,003,000	$2,147,000	$2,692,000
Amortization Of Securities	$-1,345,000	$-1,141,000	$-894,000	$-170,000
Depreciation Amortization Depletion	$105,000	$85,000	$151,000	$367,000
Depreciation And Amortization	$105,000	$85,000	$151,000	$367,000
Earnings Losses From Equity Investments	$1,958,000	$3,197,000	$5,284,000	$10,005,000
Gain Loss On Investment Securities	$-27,141,000	$33,377,000	-	-
Gain Loss On Sale Of PPE	$0	$-5,000	$0	$-22,000
Net Income From Continuing Operations	$-15,283,000	$-62,293,000	$-27,029,000	$-41,307,000
Gain Loss On Sale Of Business	-	-	-	$0

Fetched: 2026-06-20